Immunotherapy can fire up a protein that disables a T cell attack
Lung cancer immunotherapy triggers a counterattack by a surface protein found on the tumors of some patients that stifles the immune...
Collaboration yields comprehensive CAR T-cell therapy pediatric...
Almost one year after the Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell therapy for children...
MD Anderson once again named No. 1 for cancer care
MD Anderson Cancer Center again has been ranked No. 1 for cancer care by U.S. News & World Report’s annual “Best Hospitals” survey...
Communication skills may help keep research trainees on the...
A well-trained research workforce is essential for addressing both current and future health challenges in the U.S. However, according...
New venture will lead to new treatments for chemotherapy's...
MD Anderson Cancer Center and Accelerator Life Science Partners, a leading life science investment and management firm, have launched...
Uncovering an enemy of lung cancer immunotherapy
MD Anderson researchers have uncovered a genetic condition that thwarts the most common immunotherapy used against lung cancer,...